JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

A

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

A

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

A

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

A

133.89

-1.33%↓

JNJ

227.84

+1.49%↑

ISRG

522.43

-0.51%↓

ABT

105.93

-2.09%↓

MDT

100.66

-0.05%↓

A

133.89

-1.33%↓

Search

Quanterix Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

6.69 0.75

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

6.3

Max

6.77

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-3.5M

-34M

Pardavimai

16M

40M

Pelno marža

-83.479

Darbuotojai

471

EBITDA

5.7M

-31M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+8.38% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-03-16

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

108M

346M

Ankstesnė atidarymo kaina

5.94

Ankstesnė uždarymo kaina

6.69

Naujienos nuotaikos

By Acuity

50%

50%

148 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Quanterix Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-27 23:07; UTC

Uždarbis

Texas Instruments Says Data Centers, Industrial Recovery Driving Growth into 1Q -- Update

2026-01-27 21:27; UTC

Uždarbis

Texas Instruments 4Q Sales Rise, Profit Falls

2026-01-27 23:55; UTC

Rinkos pokalbiai

Yen Weakens Slightly on Possible Technical Correction -- Market Talk

2026-01-27 23:47; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-27 23:47; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Caution Over Earnings -- Market Talk

2026-01-27 23:39; UTC

Rinkos pokalbiai

Gold Falls on Likely Technical Correction, Possible Profit-Taking -- Market Talk

2026-01-27 23:20; UTC

Uždarbis

SK Innovation: Asset-Impairment Losses Weighed on Earnings

2026-01-27 23:20; UTC

Uždarbis

SK Innovation: Industry Downturn, Narrower Profit Margins Weighed on Earnings

2026-01-27 23:19; UTC

Uždarbis

SK Innovation Posts Net Loss for Second Consecutive Year

2026-01-27 23:19; UTC

Uždarbis

SK Innovation 2025 Loss KRW5.406T Vs. Loss KRW2.372T >096770.SE

2026-01-27 23:18; UTC

Uždarbis

SK Innovation 2025 Oper Pft KRW448.07B Vs. Pft KRW356.07B >096770.SE

2026-01-27 23:18; UTC

Uždarbis

SK Innovation 2025 Rev KRW80.296T Vs. KRW74.243T >096770.SE

2026-01-27 23:11; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-27 23:11; UTC

Rinkos pokalbiai

Alkane Resources Bull Positive on Outlook in Red-Hot Gold Market -- Market Talk

2026-01-27 23:07; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Freightways's Australian M&A Adds Ballast to Bull's View -- Market Talk

2026-01-27 22:17; UTC

Rinkos pokalbiai

U.S. Dollar Slips Following Trump Comments -- Market Talk

2026-01-27 22:06; UTC

Uždarbis

Boeing's Stepped-Up Plane Deliveries Lift Sales -- Update

2026-01-27 21:51; UTC

Uždarbis

Texas Instruments Stock Jumps on Strong Outlook -- Barrons.com

2026-01-27 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-27 21:43; UTC

Uždarbis

RTX Stock Jumps After Earnings. It Has 'Great Momentum,' Says CEO. -- Barrons.com

2026-01-27 21:41; UTC

Uždarbis

GM Lost Billions on EVs, Still Beat Wall Street's Expectations -- 5th Update

2026-01-27 21:38; UTC

Uždarbis

These Stocks Are Today's Movers: UnitedHealth, Humana, Micron, Corning, CoreWeave, UPS, GM, and More -- Barrons.com

2026-01-27 21:32; UTC

Uždarbis

Ampol: Modest Profit From F&I International in 2025

2026-01-27 21:32; UTC

Uždarbis

Ampol: F&I Australia Ebit Up by High Single Digit Percent in 2025

2026-01-27 21:31; UTC

Uždarbis

Ampol: New Zealand Ebit in 2025 In Line With Prior Year

2026-01-27 21:31; UTC

Uždarbis

Ampol: Australia Convenience Retail Ebit Up Mid-Single Digit Percent in 2025

2026-01-27 21:30; UTC

Uždarbis

Ampol 4Q Lytton Refinery Production 1.56 Billion Liters

2026-01-27 21:29; UTC

Uždarbis

Ampol FY Unaudited Replacement-Cost Ebitda A$1.44 Billion

2026-01-27 21:29; UTC

Uždarbis

Ampol FY Unaudited Replacement-Cost Operating Profit A$945 Million

2026-01-27 21:28; UTC

Uždarbis

Ampol 4Q Lytton Refiner Margin US$15.14/Bbl

Akcijų palyginimas

Kainos pokytis

Quanterix Corp Prognozė

Kainos tikslas

By TipRanks

8.38% į viršų

12 mėnesių prognozė

Vidutinis 7.5 USD  8.38%

Aukščiausias 8 USD

Žemiausias 7 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Quanterix Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

2 ratings

0

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

5.34 / 6.015Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

No Evidence

Rinkos nuotaikos

By Acuity

148 / 352 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Quanterix Corp

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
help-icon Live chat